Hepatitis B pp 161-174 | Cite as

Hepatitis B Vaccine Trials, Experience and Review

  • Robert E. Weibel

Abstract

Demonstrating the relationship between Australia antigen and hepatitis B virus in the late 1960’s created a serologic means for detecting hepatitis B infection, disease, carriers, and recovery (1,2). This information provided an impetus for vaccine development even in the absence of a means to propagate the virus in the laboratory. Individuals chronically infected with hepatitis B could be identified and their infected plasma containing infectious hepatitis B virus (HBV) or Dane particles and excess hepatitis B surface antigen (HBsAg) obtained by plasmaphoresis (3). Additional markers (shown in Figure 1) of human hepatitis B infection and recovery were further identified as important serologic markers. These include hepatitis B surface antigen (HBsAg) and its antibody (anti-HBs), hepatitis B core antigen and its antibody (anti-HBc), and the hepatitis Beantigen and its antibody (anti-HBe). By use of these and other tests, it is possible to identify susceptibles from immunes and the probable state of infection of the carriers. Persons who have never had hepatitis B are free of all markers.

Keywords

Protective Efficacy Vaccine Trial Untoward Effect Seroconversion Rate Core Antigen 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Prince, A. M. (1968). An antigen detected in the blood during the incubation period of serum hepatitis, Proc. Natl. Acad. Sci. 60:814–821.PubMedCrossRefGoogle Scholar
  2. 2.
    Krugman, S., et al. (1971). Viral hepatitis, type B (MS-2 strain). Studies on active immunization. J. Am. Med. Assoc. 217:41–45.CrossRefGoogle Scholar
  3. 3.
    Vyas, G. N., Cohen, S. N., and Schmid, R. (1978). Viral Hepatitis: A Contemporary Assessment of Etiology, Epidemiology, Pathogenesis and Prevention, Franklin Institute Press, Philadelphia.Google Scholar
  4. 4.
    McAuliffe, V. J., et al. (1980). Type B hepatitis: A review of current prospects for a safe and effective vaccine. Rev. Infect. Dis. 2:470–492.PubMedCrossRefGoogle Scholar
  5. 5.
    Hilleman, M. R., McAlleer, W. J., and McLean, A. A. (1981). Human Hepatitis B Vaccine, Proc. Europ. Symp. on Hepatitis B, KPR Inform/Media, New York, pp. 120–139.Google Scholar
  6. 6.
    Szmuness, W., et al. (1978). Hepatitis B vaccine. Demonstration of efficacy in a controlled clinical trial in a high risk population in the United States. N. Engl. J. Med. 303:833–841.CrossRefGoogle Scholar
  7. 7.
    Francis, D. P., et al. (1982). The prevention of hepatitis B with vaccine. Report of the Centers for Disease Control multi-center efficacy trial among homosexual men. Ann. Intern. Med. 97:362–366.PubMedCrossRefGoogle Scholar
  8. 8.
    Szmuness, W., Alter, J. H., and Maynard, J. E. (1981). Viral Hepatitis, 1981 International Symposium, Franklin Institute Press, Philadelphia.Google Scholar
  9. 9.
    Morbidity and Mortality Weekly Report 31:317–322; 327–328, 1982.Google Scholar

Copyright information

© Springer Science+Business Media New York 1984

Authors and Affiliations

  • Robert E. Weibel
    • 1
  1. 1.The Joseph Stokes, Jr. Research InstituteThe Children’s Hospital of PhiladelphiaPhiladelphiaUSA

Personalised recommendations